Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Part of paid clinical trials in St Louis, Missouri.
- Sponsor
- Washington University School of Medicine
- Study ID
- NCT07462507
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Brain Metastases
- Central Nervous System Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- [C-11]-CS1P1 — DRUG* The investigational radiotracer \[C-11\]-CS1P1 is an S1P1 PET imaging agent. * The PET imaging will be acquired either in a PET/MR scanner or the PET/CT scanner
- Brain MRI — DEVICEOptional
Study Details
Adult patients with primary or secondary central nervous system malignancies will be invited to undergo a baseline \[C-11\]-CS1P1 PET scan and a follow-up scan within 24 months of the baseline scan (preferably within 6-months post-treatment).The study will describe patterns of tracer uptake in tumors and normal brain and explore how these patterns relate to MRI findings, treatments received, and clinical outcomes.
Key Dates
- Start date
- Apr 16, 2026
- Status verified
- Apr 2026
- Primary completion
- Jun 30, 2031
- Completion
- Jun 30, 2033
Study Design
- Enrollment
- 104 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- DIAGNOSTIC
Arms
- Experimental: [C-11]-CS1P1 PETC-11\]-CS1P1 PET image acquisition up to 90 minutes will be acquired at baseline and at follow-up visit within 24 months (preferably within 6 months post treatment), along with an optional brain MRI.
Primary Outcome Measure
[C-11]CS1P1 Standardized uptake value (SUV) ratio of tumor to non-tumor regions of interest (ROIs) [ Time Frame: Baseline ]
Central Contacts
- Tammie L.S. Benzinger, M.D., Ph.D.314-362-6110
- Jayashree Rajamanickam314-273-6140
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Washington University School of Medicine | St Louis | Missouri | 63110 | Tammie L.S. Benzinger, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR) Hongyu An, Ph.D. (SUB_INVESTIGATOR) G. Richard Benzinger, M.D., Ph.D. (SUB_INVESTIGATOR) Matthew R Brier, M.D., Ph.D. (SUB_INVESTIGATOR) Yong Wang, Ph.D. (SUB_INVESTIGATOR) Qing Wang, Ph.D. (SUB_INVESTIGATOR) Jiayi Huang, M.D. (SUB_INVESTIGATOR) Zhude Tu, Ph.D. (SUB_INVESTIGATOR) Richard Laforest, Ph.D. (SUB_INVESTIGATOR) C. Ryan King, M.D., Ph.D. (SUB_INVESTIGATOR) Esther Lu, Ph.D. (SUB_INVESTIGATOR) |
Find similar trials in St Louis, MO
By research site
Related Studies
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain MetastasesPHASE3 · Recruiting · Canadian Cancer Trials Group · Tucson, Arizona
- REMASTer: REcurrent Brain Metastases After SRS TrialRecruiting · Monteris Medical · Los Angeles, California
- Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesPHASE1/PHASE2 · Recruiting · Institut de Recherches Internationales Servier · Gilbert, Arizona